Valisure proudly recognizes the longstanding partnership and continued support of Congresswoman Rosa DeLauro, who represents Connecticut’s Third Congressional District and serves as a national leader in championing healthcare transparency, consumer protection, and biomedical innovation. Her tireless advocacy aligns closely with Valisure’s mission to bring greater accountability and quality assurance to the pharmaceutical industry.

A Champion for Mandatory Recall Authority

Among Congresswoman DeLauro’s most impactful initiatives is her sponsorship of the Recall Unsafe Drugs Act, a critical piece of legislation designed to grant the FDA mandatory recall authority over drug products linked to serious health risks or death. Her advocacy was further reinforced in a joint communication with Valisure Co-Founder & President David Light to former FDA Commissioner Dr. Stephen Hahn and HHS Secretary Alex Azar, urging the withdrawal of ranitidine-containing products following Valisure’s discovery of NDMA contamination—a probable human carcinogen.

Her leadership contributed to a significant policy milestone: the February 2022 inclusion of a provision in the America COMPETES Act, which officially empowered the FDA with mandatory recall authority—a long-overdue advancement in pharmaceutical oversight.

Public Engagement and Education

Congresswoman DeLauro has actively joined Valisure in press conferences, webinars, and media campaigns, working alongside public health advocates such as Joe Graedon, Dr. Jon Ernstoff, and David Light. She played a central role in raising public awareness about ranitidine contamination, participating in events such as Joe Graedon’s national webinar and a feature segment on CBS’ The Doctors.

A Vocal Advocate for Industry Accountability

In March 2023, Congresswoman DeLauro continued her oversight efforts by writing to FDA Commissioner Dr. Robert Califf, requesting clarity on the agency’s investigation into GlaxoSmithKline’s actions regarding Zantac. Her inquiry, covered by Bloomberg, underscored the ongoing need for transparency, accountability, and enforcement in the pharmaceutical industry—particularly in light of past revelations around NDMA.

Recent Recognition and Continued Collaboration

In addition to her policy and public health efforts, Congresswoman DeLauro has remained a visible and vocal supporter of Valisure:

• She was quoted in Valisure’s 2024 press release on benzoyl peroxide products, which detailed how the acne treatment ingredient degrades into benzene—a known carcinogen—at high temperatures.
• She attended Valisure’s ribbon-cutting ceremony for its new laboratory in New Haven, Connecticut, where she delivered remarks highlighting the importance of independent quality testing and regulatory innovation.

“We must ensure the medications and consumer products we use every day are free from dangerous contaminants. I commend Valisure for their vigilance in uncovering and reporting these threats to public health,” — Congresswoman Rosa DeLauro

‍